RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START
San Fran,
Thank you.
To address your question, yes and no. The reason this is competitive is that it is a lipid binding peptide. The reason they are saying that it has aplications in both LDL and HDL is a bit more complicated. These pepetides and full length proteins are class A alpha helices which mean they have a high affinity for lipids whether those lipids are in an LDL particle, HDL particle or free cholesterol. The question is how do they get rid of them. Once a partcile becomes mature meaninh spherical and lipid packed into its core, it has to take it somewhere to drop it off. It takes it to the liver and unloads it. To unload it, the liver cell and the particle have to have a way of lining up. Apoa-1 uses a few but primarily two distinct "cell surface receptor mediated" pathways. This means that they use two different lock and keys. They are called ABCA-1 and SR-B1. For the liver primarily it uses SR-B1.
So why does that matter? Well, LDL particles also have to offload cholesterol. They use a different pathway but with a similar function. If this pathway is impaired, the LDL can't offload its cholesterol. This may seem like a good thing, but normal LDL is not bad. If the particle cant offload its cholesterol, more cholestrol is made. So this particle also has the ability to offload cholesterol using the LDL receptor. But because it can also bind to lipids within an atheroma, it competes with RVX. It may even be able to use the same SR-B1 pathway as well.
I realize this is a bit in the weeds, but in my opinion this will "technically" be competive to 208. There are dozens of these types of programs going on that most people arent aware of. As long as 208 gets to market, it will sell.